Showing results (761-770 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|September 16, 2004
CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responsesTao Yan, Anand B Desai, James W Jacobberger, et al.
Molecular Cancer Therapeutics|September 16, 2004
Down-regulation of SNAIL suppresses MIN mouse tumorigenesis: modulation of apoptosis, proliferation, and fractal dimensionHemant K Roy, Patrick Iversen, John Hart, et al.
Molecular Cancer Therapeutics|September 16, 2004
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activityCarlos A Lopez, Eric T Kimchi, Helena J Mauceri, et al.
Molecular Cancer Therapeutics|September 16, 2004
Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporationYo-Ichi Yamashita, Mitsuo Shimada, Ryosuke Minagawa, et al.
Molecular Cancer Therapeutics|March 16, 2005
Identification of biomarkers for tumor endothelial cell proliferation through gene expression profilingJames S Hardwick, Yi Yang, Chunsheng Zhang, et al.
Molecular Cancer Therapeutics|March 16, 2005
Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16Gregory N Fuller, Xiaohua Su, Roger E Price, et al.
Molecular Cancer Therapeutics|March 16, 2005
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic targetNick Loizos, Yan Xu, Jim Huber, et al.
Molecular Cancer Therapeutics|March 16, 2005
Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cellsYiwei Li, Xin Hong, Maha Hussain, et al.
Molecular Cancer Therapeutics|March 16, 2005
A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3Xenia Jimenez, Dan Lu, Laura Brennan, et al.
Molecular Cancer Therapeutics|March 16, 2005
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and BimMalti Nikrad, Thomas Johnson, Hamsa Puthalalath, et al.
Pageof 599